| Joshua R Duncan, MD, MPH | |
|
2900 Doolittle Dr, Ellsworth Afb, SD 57706-4821 | |
| (605) 385-3466 | |
| Not Available |
| Full Name | Joshua R Duncan |
|---|---|
| Gender | Male |
| Speciality | Preventive Medicine - Public Health & General Preventive Medicine |
| Location | 2900 Doolittle Dr, Ellsworth Afb, South Dakota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1871737957 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 25979 (Nebraska) | Secondary |
| 2083P0901X | Preventive Medicine - Public Health & General Preventive Medicine | 25979 (Nebraska) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Joshua R Duncan, MD, MPH 2900 Doolittle Dr, Ellsworth Afb, SD 57706-4821 Ph: (605) 385-3466 | Joshua R Duncan, MD, MPH 2900 Doolittle Dr, Ellsworth Afb, SD 57706-4821 Ph: (605) 385-3466 |
News Archive
In a medical breakthrough scientists have found a protein called perforin that kills rogue cells in the human body especially the ones causing cancer. The team comprising of experts from Melbourne and London found that perforin punches holes and kills these cells. The research appeared in the acclaimed journal Nature.
Affymetrix, Inc. today began shipping its FDA-cleared Gene Profiling Reagents. Affymetrix also announced the availability of the new Gene Profiling Array cGMP U133 P2, a version of the widely cited Human Genome U133 Plus 2.0 Array, as another component to its GeneChip Instrument System, which is used by Affymetrix partners for assay development.
The U.S. Food and Drug Administration today updated its website www.fda.gov with information about triclosan, a common ingredient added to many consumer products to reduce or prevent bacterial contamination. It may be found in antibacterial soaps and body washes, toothpastes and some cosmetics—products regulated by the FDA.
Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3 trial evaluating denosumab administered subcutaneously versus Zometa(R) (zoledronic acid) administered as an intravenous infusion in the treatment of bone metastases in 1,776 advanced cancer patients with solid tumors (not including breast and prostate cancer) or multiple myeloma. These results were presented today at the 2009 ECCO 15 - ESMO 34 European Multidisciplinary Congress in Berlin, Germany (Abstract Number: 20LBA).
Wolters Kluwer, a leading global provider of information and point of care solutions for the healthcare industry, today announced a strategic alliance with the National Student Nurses' Association, Inc. that will leverage its trusted NCLEX® content, including Lippincott NCLEX-RN PassPoint, to help nursing students better prepare for the exam.
› Verified 9 days ago
Dr. Randy Jean Guliuzza, MD Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 2900 Doolittle Dr, Ellsworth Afb, SD 57706 Phone: 605-385-3663 |